CACNA1C Gene Brugada Syndrome Type 3 NGS Genetic DNA Test
Understanding Brugada Syndrome Type 3 Genetic Testing
The CACNA1C Gene Brugada Syndrome Type 3 NGS Genetic DNA Test represents a breakthrough in cardiac genetic diagnostics, specifically designed to identify mutations in the CACNA1C gene that cause Brugada syndrome type 3. This inherited cardiac condition is characterized by abnormal electrical activity in the heart, leading to an increased risk of sudden cardiac death, particularly in young adults. Our advanced Next-Generation Sequencing technology provides comprehensive analysis of the CACNA1C gene, offering crucial insights for diagnosis, risk assessment, and family planning.
What This Test Detects and Measures
This specialized genetic test focuses on identifying pathogenic variants in the CACNA1C gene, which encodes the alpha-1C subunit of the L-type calcium channel. The test specifically detects:
- Point mutations and small insertions/deletions in the CACNA1C gene
- Genetic variations associated with impaired cardiac calcium channel function
- Mutations that disrupt normal cardiac action potential
- Genetic markers linked to increased risk of ventricular arrhythmias
- Inherited patterns of Brugada syndrome type 3
Advanced NGS Technology
Our Next-Generation Sequencing approach provides unparalleled accuracy in detecting even the most subtle genetic variations, ensuring comprehensive coverage of the CACNA1C gene with exceptional sensitivity and specificity.
Who Should Consider This Genetic Test
This test is recommended for individuals experiencing specific symptoms or with particular risk factors:
- Patients with unexplained syncope or fainting episodes
- Individuals with family history of sudden cardiac death
- Those with abnormal ECG patterns suggestive of Brugada syndrome
- Patients with documented ventricular arrhythmias
- Individuals with family members diagnosed with Brugada syndrome
- Young adults with unexplained seizures or nocturnal agonal respiration
- Patients with fever-induced cardiac symptoms
Key Benefits of CACNA1C Genetic Testing
Undergoing this comprehensive genetic analysis provides numerous advantages for patients and their families:
- Early Risk Identification: Detect genetic predisposition before symptoms manifest
- Personalized Treatment Planning: Guide appropriate medical management and interventions
- Family Screening: Enable proactive testing for at-risk relatives
- Sudden Death Prevention: Implement preventive measures for high-risk individuals
- Reproductive Planning: Make informed decisions about family planning
- Psychological Relief: Provide clarity and reduce uncertainty about cardiac risk
Understanding Your Test Results
Your genetic test results will be carefully interpreted by our team of certified genetic counselors and cardiologists:
Positive Result
A positive result indicates the presence of a pathogenic mutation in the CACNA1C gene. This finding confirms the genetic basis of Brugada syndrome type 3 and enables:
- Implementation of appropriate cardiac monitoring
- Consideration of preventive therapies
- Family member screening recommendations
- Lifestyle modification guidance
Negative Result
A negative result suggests no pathogenic mutations were detected in the CACNA1C gene. However, this does not completely rule out Brugada syndrome, as other genetic or non-genetic factors may be involved.
Variant of Uncertain Significance (VUS)
Some results may identify genetic variations with unclear clinical significance. In such cases, ongoing monitoring and family studies may be recommended.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | CACNA1C Gene Brugada Syndrome Type 3 NGS Genetic DNA Test |
| Regular Price | $700 USD |
| Discount Price | $500 USD |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type | Blood, Extracted DNA, or One Drop Blood on FTA Card |
| Testing Method | Next-Generation Sequencing (NGS) |
Pre-Test Requirements
Before scheduling your test, we recommend:
- Comprehensive clinical history documentation
- Genetic counseling session with our certified specialists
- Development of a detailed family pedigree chart
- Discussion of potential implications and limitations
- Informed consent process
Nationwide Availability
GGC DNA has testing facilities conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified collection centers ensures accessible testing for patients nationwide.
Take Control of Your Cardiac Health Today
Don’t wait to address potential cardiac genetic risks. Early detection through the CACNA1C Gene Brugada Syndrome Type 3 NGS Genetic DNA Test can provide life-saving information for you and your family. Our team of genetic specialists and cardiologists are ready to guide you through the testing process and help interpret your results.
Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic counseling session and book your test. Take the first step toward understanding your cardiac genetic profile and protecting your heart health for years to come.
